Stock VINC VINCERX PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
0.81 USD +9.46% Intraday chart for Vincerx Pharma, Inc. +35.00% -31.36%
05-14 Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-26 Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday
Vincerx Pharma Prices Public Offering of Shares, Warrants
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
Top Premarket Decliners
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell
Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research Annual Meeting 2024
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Vincerx Pharma Shares Jump After Results of Blood Cancer Treatment Trial
Top Premarket Gainers
Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Sector Update: Health Care Stocks Mixed Premarket Thursday
Vincerx Pharma Doses First Patient in Early-Stage Trial of Blood Cancer Drug Candidate
Sector Update: Health Care Stocks Slipping Late Afternoon
Sector Update: Health Care Stocks Lower in Afternoon Trading
Vincerx Pharma Says US FDA Approved Phase 1 Trial for Potential Acute Myeloid Leukemia Treatment
Vincerx Pharma, Inc. Announces FDA Clearance of IND for VIP943
Vincerx Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Vincerx Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VINC Stock
  4. News Vincerx Pharma, Inc.
  5. Other languages